Targeting of molecules to large vessel endothelium using EPCR

Details Targeting of molecules to large vessel endothelium using EPCR Targeting of molecules to large vessel endothelium using EPCR

2005-10-11

2005-10-11

Kaushal, Sumesh (Department: 1636)

Drug, bio-affecting and body treating compositions

In vivo diagnosis or in vivo testing

Testing efficacy or toxicity of a compound or composition

C424S178100, C424S179100, C424S181100, C424S183100, C435S069100, C435S320100, C435S325000, C435S455000, C514S002600, C514S04400A

Reexamination Certificate

active

06953568

ABSTRACT:
Endothelial protein C receptor (EPCR) is found primarily on endothelial cells of large vessels. EPCR translocates from the plasma membrane surface to the nucleus. Molecules which bind to EPCR can be carried from the plasma membrane surface to the nucleus. These molecules include antibodies to EPCR and activated protein C. Protein C, which also binds to EPCR, can be internalized by endothelial cells, but does not enter the nucleus. Thus, EPCR translocation from the plasma membrane to the nucleus provides a means of delivering nucleic acid such as DNA, proteins such as transcription factors, diagnostic agents or other types of drugs to the nucleus of endothelial cells, particularly those on large blood vessels. Conjugates of the materials to be delivered to the nucleus can be formed by ionic or covalent coupling. For example, proteins, including fusion proteins, can be directly conjugated to an anti-EPCR monoclonal antibody. Covalent attachment of positively charged polymers, such as polylysine, to an anti-EPCR antibody allows nucleic acid to bind by ionic charges. Steptavidin and biotin can also be used to conjugate molecules to anti-EPCR antibodies. These conjugated antibodies are transported to the nucleus by EPCR. Eamples demonstrate selective transport to the nucleus which is mediated by EPCR. Molecules transported include activated protein C, antibodies to EPCR, and steptavidin-biotin conjugates. Modification of anti-EPCR monoclonal antibodies by covalently coupling to polylysine allows binding of an expression vector to the modified antibody and translocation to the nucleus.

REFERENCES:
patent: 3625214 (1971-12-01), Higuchi
patent: 4244946 (1981-01-01), Rivier et al.
patent: 4305872 (1981-12-01), Johnston et al.
patent: 4316891 (1982-02-01), Guilleman et al.
patent: 4629784 (1986-12-01), Stammer
patent: 4782137 (1988-11-01), Hopp et al.
patent: 4789734 (1988-12-01), Pierschbacher
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4906474 (1990-03-01), Langer et al.
patent: 4925673 (1990-05-01), Steiner et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5009889 (1991-04-01), Taylor et al.
patent: 5136916 (1992-08-01), Shibukawa
patent: 5202253 (1993-04-01), Esmon et al.
patent: 5225537 (1993-07-01), Foster
patent: 5254532 (1993-10-01), Schwarz et al.
patent: 5298599 (1994-03-01), Rezaie et al.
patent: 5571786 (1996-11-01), Eibl et al.
patent: 5695993 (1997-12-01), Fukudome et al.
patent: 5698189 (1997-12-01), Rowe et al.
patent: 5749968 (1998-05-01), Melanson et al.
patent: 5779673 (1998-07-01), Roth et al.
patent: 5804392 (1998-09-01), Esmon et al.
patent: 5847085 (1998-12-01), Esmon et al.
patent: 5852171 (1998-12-01), Fukudome et al.
patent: 6399064 (2002-06-01), Fukudome et al.
patent: 0 318 201 (1989-05-01), None
patent: 0 687 687 (1995-12-01), None
patent: WO 89/02747 (1989-04-01), None
patent: WO 90/08556 (1990-08-01), None
patent: WO96/05303 (1996-02-01), None
patent: WO 96/05303 (1996-02-01), None
patent: WO 96/20732 (1996-07-01), None
patent: WO 96/21470 (1996-07-01), None
patent: WO 98/20041 (1998-05-01), None
patent: WO 98/55142 (1998-12-01), None
patent: WO 99/00673 (1999-01-01), None
Jans et al. Nuclear targeting by growth factors, cytokines, and their receptors: a role in signalling? Bioessays Vo.. 21(5):400-411, May 26, 1998.
Rosenkranz et al. Receptor-mediated endocytosis and nuclear transport of a transfecting DNA construct. Experimental Cell Research. vol. 199:323-329, May 1992.
Delporte et al. Triplex-Forming oligonucleotides can modulate aquaporin-5 gene expression in epithelial cells. Antisense & Nucleic Acid Drug Development. vol. 7:523-539, May 1997.
Michaud et al. Most nuclear proteins are imported by a single pathway. Experimental Cell Research vol. 208:128-136, Mar. 1993.
Antisense '97: A roundtable on the state of the industry. Nature Biotechnology. vol. 15:519-524, Jun. 15, 1997.
Rojanasakul, Y. Antisense oligonucleotide therapeutics: drug delivery and targeting. Advanced Drug Delivery Reviews. vol. 18:115-131, Jan. 1996.
Anderson, W. F. Human Gene Therapy. Nature vol. 392:25-30, Apr. 30, 1998.
Verma et al. Gene therapy-promises, problems and prospects. Nature vol. 389:239-242, Sep. 18, 1997.
Orkin et al. Report and recommendations of the panel to assess the NIH investment in research on gene therapy, Dec. 7, 1995.
Rosenberg et al, Gene Therapist, Heal Thyself. SCIENCE 287:1751, 2000.
Touchette, Gene Therapy: Not ready for prime time. Nat. Med. 2(1) 7-8, 1996.
Fukudome et al, Activation mechanism of anticoagulant protein C in large blood vessels involving the endothelial cell protein C receptor.J Exp Med. 6;187(7):1029-35, 1998.
Stearns-Kurosawa et al The endothelial cell protein C receptor. Cell surface expression and direct ligand binding by the soluble receptor(PNAS 93:10212-10216, 1996).
Abe, et al., “Granulocyte proteases and hydrogen peroxide synergistically inactive thrombomodulin of endothelial cells in vitro,”J. Lab. Clin. Med. 123(6):874-881, (1994).
ACCP/SCCM Consensus Conference, “Definitions for Spesis and Organ Failure and Guidelines for the Use of Innovative Therapies in Sepsis,”Chest101(6):1644-1655 (1992).
Agrawal, et al., “Oligodeoxynucleoside phosphoramidates and phosphorothioates as inhibitors of human immunodeficiency virus,”Proc. Natl. Acad. Sci. USA85(19):7079-7083 (1988).
Arend, et al., “Building of IL-1α, IL-1β, and IL-1 Receptor Antagonist by Soluble IL-1 Receptors and Levels of Soluble IL-1 Receptors in Synovial Fluids,”J. Immunol. 153:4766-4774 (1994).
Asakura, et al. “Plasma Levels of Soluble Thrombomodulin Increase in Cases of Disseminated Intravascular Coagulation With Organ Failure,”Am. J. Hematol. 38:281-287 (1991).
Askew, B., et al., “Molecular Recognition with Convergent Functional Groups, 6, Synthetic and Structural Studies with a Model Receptor for Nucleic Acid Components”,J. Am. Chem. Soc., 111:1082-1090 (1989).
Bangalore, et al., “High affinity binding sites for activated protein C and protein C on cultured human umbilical vein endothelial cells. Independent of protein S and distinct from known ligands,”Thromb Haemos72(3):465-74 (1994).
Berg, et al., “Aberrant RNA splicing of the protein C and protein S genes in health individuals,”Blood Coag Fibrinol. 7:625-631 (1996).
Blume, et al., “Triple helix formation by purine-rich oligonucleotides targeted to the human dihydrofolate reductase promoter,”Nucleic Acids Res. 20(7):1777-84 (1992).
Bock, P. E. “Active Site Selective Labeling of Serine Proteases with Spectroscopic Probes Using Thioester Peptide Chloromethyl Ketones: Demonstration of Thrombin Labeling Using Nα-[(Acetylthio)acetyl]-D-Phe-Pro-Arg-CH2C1,”Biochemistry27:6633-6639 (1988).
Boehme, et al., “Release of thrombomodulin from endothelial cells by concentrated action of TNF-α and neutrophils: in vivo and in vitro studies,”Immunology87:134-140 (1996).
Bourin and Lindahl, “Review Article: Glycosaminoglycans and the regulation of blood coagulation,”Biochem. J. 289:313-330 (1993).
Clackson, et al., “Making antibody fragments using phage display libraries,”Nature352:624-688 (1991).
Conway and Rosenberg, “Tumor Necrosis Factor Suppresses Transcription of the Thrombomodulin Gene in Endothelial Cells,”Mol. Cell. Biol. 8(12):5588-5592 (1988).
Cooney, et al., “Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro,”Science. 241(4864):456-9 (1988).
Crooke, et al., “Progress toward oligonucleotide therapeutics: pharmacodynamic properties,”FASEB J. 7(6):533-9 (1993).
Curtis, et al. “IL-1 and its receptor are translocated to the nucleus,”J. Immunol. 144:1295-1303 (1990).
Dahlbäck, “Inhibition of Protein CBCofactor Function of Human and Bovine Protein S by C4b-binding Protein,”J. Biol. Chem. 261(26):12022-12027 (1986).
Dahlbäck, “Protein S and C4b-Binding Protein: Compone

Affiliated with

Also associated with

Rating

Targeting of molecules to large vessel endothelium using EPCR does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Targeting of molecules to large vessel endothelium using EPCR, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Targeting of molecules to large vessel endothelium using EPCR will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3436526